ZA201206662B - Oral formulations and lipophilic salts of methylnaltrexone - Google Patents

Oral formulations and lipophilic salts of methylnaltrexone

Info

Publication number
ZA201206662B
ZA201206662B ZA2012/06662A ZA201206662A ZA201206662B ZA 201206662 B ZA201206662 B ZA 201206662B ZA 2012/06662 A ZA2012/06662 A ZA 2012/06662A ZA 201206662 A ZA201206662 A ZA 201206662A ZA 201206662 B ZA201206662 B ZA 201206662B
Authority
ZA
South Africa
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
ZA2012/06662A
Other languages
English (en)
Inventor
Syed M Shah
Eric C Ehrnsperger
Shareffi Kadum A Al
Christopher Richard Diorio
Xu Meng
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201206662(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of ZA201206662B publication Critical patent/ZA201206662B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2012/06662A 2010-03-11 2012-09-05 Oral formulations and lipophilic salts of methylnaltrexone ZA201206662B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
PCT/US2011/027913 WO2011112816A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Publications (1)

Publication Number Publication Date
ZA201206662B true ZA201206662B (en) 2026-05-27

Family

ID=44148539

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2012/06662A ZA201206662B (en) 2010-03-11 2012-09-05 Oral formulations and lipophilic salts of methylnaltrexone
ZA2018/08498A ZA201808498B (en) 2010-03-11 2018-12-18 Oral formulations and lipophilic salts of methylnaltrexone

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2018/08498A ZA201808498B (en) 2010-03-11 2018-12-18 Oral formulations and lipophilic salts of methylnaltrexone

Country Status (32)

Country Link
US (8) US8524276B2 (cg-RX-API-DMAC10.html)
EP (2) EP2371357B1 (cg-RX-API-DMAC10.html)
JP (4) JP6143409B2 (cg-RX-API-DMAC10.html)
KR (2) KR101913102B1 (cg-RX-API-DMAC10.html)
CN (2) CN107308125B (cg-RX-API-DMAC10.html)
AR (1) AR080491A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011224275B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012022873B1 (cg-RX-API-DMAC10.html)
CA (1) CA2789798C (cg-RX-API-DMAC10.html)
CL (1) CL2012002192A1 (cg-RX-API-DMAC10.html)
CO (1) CO6630134A2 (cg-RX-API-DMAC10.html)
CR (1) CR20120476A (cg-RX-API-DMAC10.html)
EA (1) EA029096B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12012208A (cg-RX-API-DMAC10.html)
ES (1) ES2623926T3 (cg-RX-API-DMAC10.html)
GE (1) GEP201606550B (cg-RX-API-DMAC10.html)
GT (1) GT201200247A (cg-RX-API-DMAC10.html)
HU (1) HUE033133T2 (cg-RX-API-DMAC10.html)
IL (1) IL221452A (cg-RX-API-DMAC10.html)
MA (1) MA34146B1 (cg-RX-API-DMAC10.html)
MX (2) MX349145B (cg-RX-API-DMAC10.html)
MY (1) MY160727A (cg-RX-API-DMAC10.html)
NZ (3) NZ601595A (cg-RX-API-DMAC10.html)
PE (1) PE20130063A1 (cg-RX-API-DMAC10.html)
PH (1) PH12012501622A1 (cg-RX-API-DMAC10.html)
PL (2) PL2371357T3 (cg-RX-API-DMAC10.html)
SG (3) SG10201501821RA (cg-RX-API-DMAC10.html)
TN (1) TN2012000392A1 (cg-RX-API-DMAC10.html)
TW (2) TWI605814B (cg-RX-API-DMAC10.html)
UA (2) UA123856C2 (cg-RX-API-DMAC10.html)
WO (1) WO2011112816A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201206662B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
TWI605814B (zh) 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
WO2013096444A1 (en) * 2011-12-19 2013-06-27 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) * 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3206491B1 (en) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2020225395A1 (en) * 2019-05-07 2020-11-12 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
EP1387673B1 (en) * 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
WO2002098422A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN1596254A (zh) * 2001-11-29 2005-03-16 先灵公司 含有增加量的旋转异构体的药物活性盐的组合物的制备方法
AU2003220290B2 (en) 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
AU2004259208B2 (en) * 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
CA2550071A1 (en) 2003-12-19 2005-07-07 Schering Corporation Pharmaceutical compositions
US20070148232A1 (en) * 2003-12-31 2007-06-28 Pfizer Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
EP1809579B1 (en) 2004-09-30 2012-08-08 Becton, Dickinson and Company Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
ATE553787T1 (de) * 2006-08-16 2012-05-15 Novartis Ag Vorübergehende lichtbleichung von farbigen linsenpflegelösungen
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
TWI605814B (zh) 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
JP2016029054A (ja) 2016-03-03
MA34146B1 (fr) 2013-04-03
EP2371357B1 (en) 2017-02-01
US20120070495A1 (en) 2012-03-22
US20140249171A1 (en) 2014-09-04
EP3178472A1 (en) 2017-06-14
MY160727A (en) 2017-03-15
JP2019034958A (ja) 2019-03-07
HUE033133T2 (en) 2017-11-28
EA029096B1 (ru) 2018-02-28
TN2012000392A1 (en) 2014-01-30
JP6429955B2 (ja) 2018-11-28
MX349145B (es) 2017-07-14
UA123856C2 (uk) 2021-06-16
US20160206612A1 (en) 2016-07-21
PH12012501622A1 (en) 2012-11-05
IL221452A (en) 2017-07-31
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
US10307417B2 (en) 2019-06-04
CL2012002192A1 (es) 2012-09-28
ECSP12012208A (es) 2015-03-31
JP2017206553A (ja) 2017-11-24
EA201270741A1 (ru) 2013-02-28
SG10201501821RA (en) 2015-05-28
JP2011190259A (ja) 2011-09-29
NZ703564A (en) 2016-08-26
TW201141479A (en) 2011-12-01
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
CR20120476A (es) 2012-11-30
NZ702826A (en) 2016-08-26
IL221452A0 (en) 2012-10-31
TWI605814B (zh) 2017-11-21
ES2623926T3 (es) 2017-07-12
CO6630134A2 (es) 2013-03-01
EP3178472B1 (en) 2021-10-27
US9314461B2 (en) 2016-04-19
CN102918039B (zh) 2017-06-09
CN107308125B (zh) 2021-07-16
AR080491A1 (es) 2012-04-11
JP6143409B2 (ja) 2017-06-07
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US20200121673A1 (en) 2020-04-23
US20190314365A1 (en) 2019-10-17
UA111717C2 (uk) 2016-06-10
KR20130010900A (ko) 2013-01-29
MX2012009125A (es) 2012-09-07
WO2011112816A1 (en) 2011-09-15
AU2011224275A1 (en) 2012-08-23
EP2371357A1 (en) 2011-10-05
CN102918039A (zh) 2013-02-06
SG10201606618PA (en) 2016-09-29
US10376505B2 (en) 2019-08-13
US20190117645A1 (en) 2019-04-25
NZ601595A (en) 2015-01-30
US8524276B2 (en) 2013-09-03
KR101913102B1 (ko) 2018-10-31
JP6647368B2 (ja) 2020-02-14
CA2789798C (en) 2020-09-22
GT201200247A (es) 2013-09-11
US10507206B2 (en) 2019-12-17
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
US20130330407A1 (en) 2013-12-12
PE20130063A1 (es) 2013-02-11
TW201622724A (zh) 2016-07-01
HK1245673A1 (zh) 2018-08-31
BR112012022873A2 (pt) 2016-08-30
MX368805B (es) 2019-10-17
GEP201606550B (en) 2016-10-10
PL2371357T3 (pl) 2017-09-29
US20190117646A1 (en) 2019-04-25
BR112012022873B1 (pt) 2021-09-14
CN107308125A (zh) 2017-11-03
SG183133A1 (en) 2012-09-27